Literature DB >> 24458374

Evaluation of commercial antibodies against human sphingosine-1-phosphate receptor 1.

Franck Talmont1, Lionel Moulédous.   

Abstract

Sphingosine-1-phosphate receptor 1 (S1P1), also called endothelial differentiation gene 1, plays an important role in migration, proliferation, and survival of several types of cells including endothelial cells and lymphocytes and is involved in multiple sclerosis. Two commercial rabbit anti-S1P1 antibodies (polyclonal and monoclonal) were tested on CHO cells expressing S1P1 receptors fused to the green fluorescent protein at the C-terminal end and on Pichia pastoris and HEK cells expressing cmyc-tagged S1P1. Polyclonal antibodies did not give any signal by Western blot, immunofluorescence, and flow cytofluorometry. Monoclonal antibodies were able to reveal an unspecific band by Western blot performed on various cell types. Consequently, in our hands and using our protocols, we show that these antibodies did not specifically detect S1P1 receptors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24458374     DOI: 10.1007/s00210-014-0957-5

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  31 in total

1.  How reliable are G-protein-coupled receptor antibodies?

Authors:  Martin C Michel; Thomas Wieland; Gozoh Tsujimoto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-01-27       Impact factor: 3.000

2.  Evaluation of primary opioid receptor antibodies for use in western blotting.

Authors:  H Niwa; D J Rowbotham; D G Lambert
Journal:  Br J Anaesth       Date:  2012-03       Impact factor: 9.166

3.  GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors.

Authors:  Lionel Moulédous; Carine Froment; Stéphanie Dauvillier; Odile Burlet-Schiltz; Jean-Marie Zajac; Catherine Mollereau
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

4.  Specificity evaluation of antibodies against human β3-adrenoceptors.

Authors:  Hana Cernecka; Peter Ochodnicky; Wouter H Lamers; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-06-12       Impact factor: 3.000

5.  Characterisation of a sphingosine 1-phosphate-activated Ca2+ signalling pathway in human neuroblastoma cells.

Authors:  Israel Ramos Villullas; Alison J Smith; Robert P Heavens; Peter B Simpson
Journal:  J Neurosci Res       Date:  2003-07-15       Impact factor: 4.164

6.  Six commercially available angiotensin II AT1 receptor antibodies are non-specific.

Authors:  Julius Benicky; Roman Hafko; Enrique Sanchez-Lemus; Greti Aguilera; Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2012-07-28       Impact factor: 5.046

7.  Lack of specificity of antibodies directed against human beta-adrenergic receptors.

Authors:  Nazha Hamdani; Jolanda van der Velden
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-01-22       Impact factor: 3.000

8.  Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice.

Authors:  Xiaoying Lu; Tamas Bartfai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-01-22       Impact factor: 3.000

9.  Evaluation of the specificity of antibodies raised against cannabinoid receptor type 2 in the mouse retina.

Authors:  Bruno Cécyre; Sébastien Thomas; Maurice Ptito; Christian Casanova; Jean-François Bouchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-05       Impact factor: 3.000

10.  Commercially available angiotensin II At₂ receptor antibodies are nonspecific.

Authors:  Roman Hafko; Sonia Villapol; Regina Nostramo; Aviva Symes; Esther L Sabban; Tadashi Inagami; Juan M Saavedra
Journal:  PLoS One       Date:  2013-07-01       Impact factor: 3.240

View more
  4 in total

1.  Rat β₃-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues.

Authors:  Hana Cernecka; Wisuit Pradidarcheep; Wouter H Lamers; Martina Schmidt; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-08-30       Impact factor: 3.000

2.  Commercially available antibodies directed against α-adrenergic receptor subtypes and other G protein-coupled receptors with acceptable selectivity in flow cytometry experiments.

Authors:  Abhishek Tripathi; Vadim Gaponenko; Matthias Majetschak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-12-14       Impact factor: 3.000

3.  Development and characterization of sphingosine 1-phosphate receptor 1 monoclonal antibody suitable for cell imaging and biochemical studies of endogenous receptors.

Authors:  Franck Talmont; Lionel Moulédous; Marion Baranger; Anne Gomez-Brouchet; Jean-Marie Zajac; Clarence Deffaud; Olivier Cuvillier; Anastassia Hatzoglou
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

4.  Nociceptin/Orphanin FQ (N/OFQ) conjugated to ATTO594: a novel fluorescent probe for the N/OFQ (NOP) receptor.

Authors:  M F Bird; R Guerrini; J M Willets; J P Thompson; G Caló; D G Lambert
Journal:  Br J Pharmacol       Date:  2018-11-06       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.